Sean P. Nolan
Sean P. Nolan's purchase track record
Sean P. Nolan has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/16/2023 | TSHA | $400K | -13.0% | -24.3% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
TSHA Valuation Debate Highlights Split Views. Recent articles discuss conflicting views on Taysha Gene Therapies' valuation, with some suggesting the stock is above fair value based on book value, while others argue it may be undervalued. This debate occurs while the stock trades near its 52-week low, reflecting significant uncertainty among investors regarding the company's true worth.
Transaction History
| VTR | ▲ Buy | Grant | 2,047 | $185K | 5/13/2026 | View on chart |
| TSHA | ▼ Sell | Open Market | 41,312 | $190K | 1/26/2026 | View on chart |
| TSHA | ▼ Sell | Open Market | 136,789 | $650K | 1/23/2026 | View on chart |
| TSHA | ▲ Buy | Grant | 1,008,000 | $0 | 1/12/2026 | View on chart |
| VTR | ▲ Buy | Grant | 2,882 | $185K | 5/13/2025 | View on chart |
| TSHA | ▲ Buy | Grant | 892,500 | $0 | 1/2/2025 | View on chart |
| VTR | ▲ Buy | Grant | 3,648 | $175K | 5/14/2024 | View on chart |
| TSHA | ▲ Buy | Grant | 1,184,688 | $0 | 1/2/2024 | View on chart |
| TSHA | ▲ Buy | Open Market | 444,444 | $400K | 8/16/2023 | View on chart |
| VTR | ▲ Buy | Grant | 3,835 | $175K | 5/16/2023 | View on chart |
| VTR | ▲ Buy | Grant | 3,056 | $175K | 4/27/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Ventas Expands Acquisition Budget to $3B, Targets 17% NOI Growth
Ventas announced it will increase its acquisition budget to $3 billion and aims for up to 17 % growth in net operating income. Barclays cut its price target to $91, citing the higher budget and the company’s strong dividend payout of over 370 % of earnings. The firm is also noted for its role in the senior‑housing shortfall, a sector that has helped REITs rebound from recent declines. Current technicals show the stock near its 200‑day moving‑average and a support level at $86.74.
Ventas Expands Acquisition Budget to $3B, Targets 17% NOI Growth. Ventas announced it will increase its acquisition budget to $3 billion and aims for up to 17 % growth in net operating income. Barclays cut its price target to $91, citing the higher budget and the company’s strong dividend payout of over 370 % of earnings. The firm is also noted for its role in the senior‑housing shortfall, a sector that has helped REITs rebound from recent declines. Current technicals show the stock near its 200‑day moving‑average and a support level at $86.74.